1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Exelixis’s Cabometyx Two-For-Two In A Week As Neuroendocrine Tumor Study Hits Endpoint

 
• By Alaric DeArment

The announcement of the CABINET study’s success follows by days positive results for CONTACT-02 in prostate cancer, though NETs represent a smaller commercial opportunity.

Exelixis said the Phase III CABINET trial in neuroendocrine tumors met its primary endpoint • Source: Shutterstock

Exelixis, Inc. got its second bit of good news in the space of a week with positive results from a pivotal trial of Cabometyx (cabozantinib) in pancreatic and extra-pancreatic neuroendocrine tumors (NETs), following closely the announcement of success in a study of the same drug in prostate cancer. On the other hand, while the NETs indication is one of significant unmet need, it may be relatively small in terms of revenue potential.

The company announced 24 August that the data and safety monitoring board (DSMB) of the National Cancer Institute-sponsored and Alliance for Clinical Trials in Oncology-led Phase III CABINET trial unanimously recommended unblinding the study early due to a “dramatic” improvement in efficacy for Cabometyx compared with placebo in patients with advanced pancreatic and extra-pancreatic NETs whose disease had progressed following prior systemic therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.